Compositions and methods for the prevention and control of insulin-induced hypoglycemia
AssigneeDiObex, Inc.
InventorsDaniel T. Green, Robert R. Henry
Life of this patent
Estimating the term…
Abstract
Pharmaceutical compositions comprising glucagon can be administered to control and treat diabetes while reducing or eliminating the risk of insulin-induced hypoglycemia. Also provided are methods of administering glucagon so as to reduce the risk of inducing hypoglycemia.
Claims20
A system for reducing the risk of hypoglycemia, said system comprising:
- a syringe for administration of glucagon to a subject;
- and
- a slow release dosage of glucagon that provides 2 to 16 ng of glucagon per kilogram of subject weight per minute to a subject, for a period of at least 1 hour, wherein said glucagon is administered subcutaneously.
A depot glucagon formulation comprising glucagon, wherein the depot glucagon formulation provides glucagon to a subject at a rate between 2 to 16 ng per kg of subject weight per minute when administered subcutaneously to the subject, wherein the subject weighs 50 to 100 kg.
A pharmaceutical composition comprising:
- insulin in an amount effective for the control of diabetes;
- and
- glucagon in an amount effective for reducing the risk of hypoglycemia in a human or other mammal, wherein said insulin is present in said composition at a ratio of insulin to glucagon of about 1 unit of insulin to between more than 0.02 milliunits up to 200 milliunits of glucagon, and wherein the glucagon is part of a slow release dosage that provides 2 to 16 ng of glucagon per kilogram of subject weight per minute to the subject wherein said glucagon is administered subcutaneously.
A method of treating diabetes in a human or other mammal without inducing hypoglycemia, said method comprising:
- administering insulin in an amount therapeutically effective for the control of diabetes, wherein said insulin is in an amount between 0.5 and 20 units of insulin;
- and administering glucagon in time and an amount therapeutically effective for reducing the risk of hypoglycemia, wherein said glucagon is administered subcutaneously, and wherein the amount of glucagon administered is 2 to 16 ng per kilogram of subject weight per minute to the subject.
A kit for the administration of glucagon and insulin in amounts to reduce the risk of hypoglycemia, said kit comprising:
- glucagon;
- insulin, wherein said glucagon and insulin are in a ratio of 1-20 units of insulin to 32-480 milliunits of glucagon;
- a means for administering glucagon subcutaneously;
- and instructions for the administration of insulin and glucagon so that the glucagon reduces the risk of a hypoglycemic event by providing 2 to 16 ng of glucagon per kilogram of subject weight per minute to the subject.
Dependencies are inferred from the claim text.